Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of nuclear factor kappa-B kinase regulatory subunit gamma (IKBKG), commonly known as NF-kappa-B essential modulator (NEMO) or IKKγ, is a non-catalytic scaffold protein that serves as the regulatory subunit of the IκB kinase (IKK) core complex. It plays an indispensable role in the canonical NF-κB signaling pathway, which is a master regulator of immune responses, inflammation, cell survival, and development. Upon stimulation by proinflammatory cytokines (such as TNF-α and IL-1β) or pathogen-associated molecular patterns, NEMO binds to polyubiquitin chains and recruits the catalytic subunits IKKα and IKKβ, facilitating their activation. This leads to the phosphorylation and subsequent proteasomal degradation of IκBα, allowing NF-κB dimers to translocate to the nucleus and drive gene transcription.\n\nDysregulation of NEMO is heavily implicated in chronic inflammatory diseases, autoimmune disorders, and various cancers, while genetic mutations in the IKBKG gene cause rare X-linked disorders such as incontinentia pigmenti and anhidrotic ectodermal dysplasia with immunodeficiency. Consequently, NEMO has emerged as an attractive therapeutic target. Pharmacological strategies primarily focus on disrupting the protein-protein interaction between NEMO and the catalytic IKK subunits using NEMO-binding domain (NBD) peptides or small-molecule mimetics (e.g., SR12343, Shikonin), thereby selectively blocking stimulus-induced canonical NF-κB activation while sparing basal, non-canonical signaling to minimize systemic toxicity.
Disruption of the protein-protein interaction between NEMO and IKKβ/IKKα to prevent IKK complex assembly and subsequent canonical NF-κB activation
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of nuclear factor kappa-B kinase regulatory subunit gamma (NEMO).